A detailed history of Legal & General Group PLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 195,638 shares of RXRX stock, worth $1.37 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
195,638
Previous 151,739 28.93%
Holding current value
$1.37 Million
Previous $1.51 Million 2.98%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$7.35 - $10.05 $322,657 - $441,184
43,899 Added 28.93%
195,638 $1.47 Million
Q1 2024

May 14, 2024

BUY
$9.13 - $15.52 $201,937 - $343,271
22,118 Added 17.06%
151,739 $1.51 Million
Q4 2023

Feb 15, 2024

BUY
$5.09 - $10.79 $58,896 - $124,851
11,571 Added 9.8%
129,621 $1.28 Million
Q3 2023

Nov 14, 2023

BUY
$6.59 - $15.86 $42,604 - $102,534
6,465 Added 5.79%
118,050 $903,000
Q2 2023

Aug 14, 2023

BUY
$4.56 - $9.94 $50,319 - $109,687
11,035 Added 10.97%
111,585 $833,000
Q1 2023

May 15, 2023

BUY
$6.42 - $9.64 $42,243 - $63,431
6,580 Added 7.0%
100,550 $670,000
Q4 2022

Feb 14, 2023

BUY
$7.16 - $12.7 $31,955 - $56,680
4,463 Added 4.99%
93,970 $724,000
Q3 2022

Nov 14, 2022

SELL
$7.83 - $13.6 $178,758 - $310,488
-22,830 Reduced 20.32%
89,507 $952,000
Q2 2022

Aug 22, 2022

BUY
$5.04 - $9.26 $240,150 - $441,229
47,649 Added 73.66%
112,337 $914,000
Q1 2022

May 16, 2022

BUY
$6.16 - $18.03 $270,639 - $792,148
43,935 Added 211.7%
64,688 $463,000
Q4 2021

Feb 14, 2022

BUY
$16.14 - $21.86 $291,278 - $394,507
18,047 Added 666.93%
20,753 $355,000
Q3 2021

Nov 15, 2021

BUY
$19.03 - $41.33 $12,464 - $27,071
655 Added 31.94%
2,706 $62,000
Q2 2021

Aug 12, 2021

BUY
$18.0 - $37.42 $36,918 - $76,748
2,051 New
2,051 $75,000

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.26B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.